Vitamin D deficency
Conditions
Interventions
Control Group:Placebo
Group 1:Single intramuscular injection of 200,000 units vitamin D2
Group 2:Single intramuscular injection of 400,000 units vitamin D2
Group 3:Single intramuscular injection of 600,000 units vitamin D2
Sponsors
The Second XiangYa Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 60 years old at the time of consent; 2. Free of liver and kidney dysfunction and other serious diseases; 3. No long-term plan in the tropics areas within six months after the start of the trial; 4. Be willing to participate in the study and sign the informed consent;
Exclusion criteria
Exclusion criteria: 1. History of any vitamin D supplements in the last 6 months; 2. Medications taken of any drugs that affect the metabolism of vitamin D (such as phenytoin, phenobarbital, rifampicin) in the last 6 months; 3. Unwilling to participate in the research; 4. Obvious cognitive impairments or physical dysfunctions that affect the completion of research projects; 5. hypercalcemia, vitamin D overdose or poisoning, renal desfunction or other diseases that affect vitamin D metabolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 25(OH)D2;25(OH)D3; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum osteocalcin;Serum parathyroid hormone;Serum ß-C-terminaltelopeptide typeIcollagen;Serum N-terminal propeptide of type I procollagen;Vitamin D binding protein; | — |
Countries
China
Contacts
Public ContactZhongjian Xie
National Clinical Research Center for Metabolic Diseases, the Second XiangYa Hospital, Central South University
Outcome results
None listed